Prevention of recurrence undergoing additional intravesical therapy with pirarubicin for non-muscule invasive bladder cancer.

Prevention of recurrence undergoing additional intravesical therapy with pirarubicin for non-muscule invasive bladder cancer. - Prevention of recurrence undergoing additional intravesical therapy with pirarubicin for non-muscule invasive bladder cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009967

Enrollment

110

Registered

2013-02-07

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-muscle invasive bladder cancer (intermediate-risk patients)

Interventions

Intravesical infusion of pirarubicin 30mg immediately after TURBTand every one time at 3,6,9,12months later.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Non-muscle invasive bladder cancer (pTa-1,G1-2/low grade). (exept for first-time case & single tumour & G1/low grade & tumour diameter<3cm) (2) Curative resection of all visible tumors can be performed. (3) No concurrent CIS (4) Patients must have functioning organs (5) Performance status scale 0-2 (6) Patients must give written informed consent

Exclusion criteria

Exclusion criteria: (1) Active multiple cancers (2) Patients with historically or presently disease of upper urinary tract urothelial cell carcinoma. (3) Target at BCG therapy (unrelated 2nd TUR) (4) Funcion of all organs are without severe dysfunction. (5) Lymph node metastasis or ogan metastasis (6) After TURBT,patients who didn`t undergo intravesical therapy with pirarubicin. (7) Patients who previously underwent intravesical therapy with BCG. (8) Inappropriate patients for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
Duration of recurrence-free survival	—

Secondary

Measure	Time frame
Two-year recurrence free survival rate Safty	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026